Reply to: “Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018”

The European Association for the Study of the Liver (EASL) read with interest the letter to the Editors by Stamm et al. The authors of the letter conclude that “the 12-week, single-tablet regimen of sofosbuvir/velpatasvir […] is a highly effective treatment for all patients with compensated liver disease, irrespective of genotype, extent of liver fibrosis or prior interferon treatment history”. This statement is too simplistic as the combination of s ofosbuvir and velpatasvir without ribavirin is suboptimal in patients with cirrhosis infected with HCV genotype 3 carrying the Y93H resistance-associated substitution (RAS) in the NS5A region of the viral genome (whether detected by population sequencing or>15% by deep sequencing) at treatment baseline.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research